Intellia’s in vivo gene therapy victorious in Phase III HAE trial
Intellia’s CEO said that the trial marks the first positive Phase III readout for an in vivo CRISPR gene therapy.
28 April 2026
28 April 2026
Intellia’s CEO said that the trial marks the first positive Phase III readout for an in vivo CRISPR gene therapy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.